── About Us ──
Linden Asset Group (LAG), established in 2019, specializes in investing in the cutting-edge sectors of global biomedical sciences, seeking breakthrough investment opportunities. LAG has invested in 15 outstanding companies, with the total AUM (asset under management) over RMB 2 billion.
The investment management team comprises alumni from elite universities worldwide, possessing professional scientific expertise and extensive experience in significant financial institutions across both domestic and international markets.
LAG upholds a deep respect for science and life, striving to identify and foster exceptional medical innovation enterprises to alleviate patient suffering.
── Focus On Value-based Care ──
LAG is committed to harnessing the transformative power of technological innovation within China's life sciences sector, capturing opportunities presented by the era of value-based healthcare.
Cancer Treatment
China reports the highest global incidence and mortality rates for cancer, placing significant health burdens and unmet treatment needs on patients.
LAG focuses on advancements in cancer screening, diagnosis, innovative pharmaceuticals, and therapeutics.
Anti-Epidemic
The COVID-19 pandemic has heightened public awareness regarding viruses and epidemic prevention, with leading vaccine technologies representing a national strategic scientific prowess.
LAG focuses on mRNA technology, vaccine platforms, and nucleotide pharmaceuticals, etc.
Cardio-Cerebral Disease Treatment
In the 21st century, cardiac-cerebral vascular diseases rank as the leading causes of death globally, with incidence rates increasing each year. This represents one of the significant challenges in the field of global healthcare.
LAG focuses on heart valve technology, AI imaging, and artificial hearts, etc.
Anti-Aging
Accelerating population aging poses significant societal challenges, with aging being the primary risk factor for numerous chronic diseases. Technological advancements can slow the aging process.
LAG focuses on cell therapy, gene editing, and regenerative medicine technology, etc.
── Contact Us ──
── Portfolio ──
苏公网安备32010502010504号